LAB missed EPS expectations by 27.30%
Feb 27, 2025, 11:32 AM
0.00%
What does LAB do
Standard BioTools, headquartered in South San Francisco, offers biotechnology tools and services for clinical research, focusing on proteomics and genomics with 534 employees since its IPO in 2011. The company provides insights into health and disease using advanced technologies for diverse applications in translational and clinical research.
Standard BioTools (LAB) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Standard BioTools's actual EPS was -$0.09, missing the estimate of -$0.07 per share, resulting in a -27.30% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.